Difference between revisions of "HP802-247"
m |
m |
||
| Line 28: | Line 28: | ||
[[Category:Foreskin Products]] | [[Category:Foreskin Products]] | ||
[[Category:Financial Gain]] | [[Category:Financial Gain]] | ||
| − | |||
| + | [[Category:From CircLeaks]] | ||
[[Category:From IntactWiki]] | [[Category:From IntactWiki]] | ||
Revision as of 15:55, 14 September 2019
HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.[1]
HP802-247
The new spray (HP802-247) consisted of a combination of donated skin cells and proteins.
The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.[2]
The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the skin, and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.
References
- ↑
(3 August 2012). Spray-on-skin' treatment for leg ulcers
, NHS. Retrieved 24 November 2012. - ↑ (November 2024).
Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
, The Lancet. Retrieved 24 November 2012.
